文献速递艾滋病与性传播感染

HIV病毒血症未抑制者直接启动长效卡博特韦联合利匹韦林:一项随机试验

Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial.
PubMed 文献 · Clin Infect Dis · 2026-09-01

这项多中心开放标签随机试验纳入口服ART经验且HIV-1 RNA≥200拷贝/mL的感染者,比较立即启动LA CAB+RPV与继续口服ART至第24周再切换的疗效。第24周病毒抑制率在立即启动组为88.0%(22/25),延迟切换组为55.0%(11/20),未达抑制的相对风险0.27(95%CI 0.08-0.86;p=0.026),效果持续至第52周。

要点

  • 对依从性困难且病毒血症未抑制者,立即启动LA CAB+RPV较继续口服ART提高第24周病毒抑制率。
  • 第24周病毒抑制率:立即组88.0% vs 延迟组55.0%,未达抑制相对风险0.27(95%CI 0.08-0.86;p=0.026)。
  • LA CAB+RPV的病毒抑制效果持续至第52周。

核心结论

  • 在依从性困难相关的HIV病毒血症者中,立即启动LA CAB+RPV比继续口服ART获得更高的病毒抑制率。
  • 结果支持LA CAB+RPV应用于病毒稳定抑制以外的人群。

研究设计与样本

  • 多中心、开放标签、随机研究,比较立即启动LA CAB+RPV与继续标准口服治疗至第24周(延迟切换组)。
  • 纳入口服ART经验、HIV诊断至少12个月且最近HIV-1 RNA≥200拷贝/mL的感染者,排除对CAB或RPV耐药相关突变者。
  • 61例随机化,45例符合标准并纳入分析;91%为男性,基线HIV-1 RNA中位数35,000拷贝/mL。

主要发现

  • 第24周HIV-1 RNA<200拷贝/mL的比例:立即LA组88.0%(22/25),延迟切换组55.0%(11/20)。
  • 未达病毒抑制的相对风险为0.27(95%CI 0.08-0.86;p=0.026),利于立即LA组。
  • LA CAB+RPV的效果持续至第52周。

关键数值与推荐

  • 主要终点为第24周HIV-1 RNA<200拷贝/mL的参与者比例。
  • 第24周病毒抑制率88.0%(22/25)vs 55.0%(11/20),未达抑制相对风险0.27(95%CI 0.08-0.86;p=0.026)。

临床怎么用

  • 对口服ART依从性困难且病毒血症未抑制、无CAB/RPV耐药相关突变者,可考虑立即启动LA CAB+RPV。
  • 启动前应排除对CAB或RPV的耐药相关突变。

局限性

  • 开放标签设计。
  • 随机化61例中仅45例符合标准并纳入分析,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-acting injectable cabotegravir plus rilpivirine (LA CAB+RPV) is approved for virally suppressed people with human immunodeficiency virus (HIV), but evidence for its use in those with persistent viremia and adherence challenges remains limited. METHODS: We conducted a multicenter, open-label, randomized study involving oral antiretroviral therapy (ART)-experienced people with HIV who had been diagnosed with HIV for at least 12 months and a most recent HIV-1 RNA level of at least 200 copies per milliliter. Participants with resistance-associated mutations to CAB or RPV were excluded. Eligible participants were randomly assigned in a 1:1 ratio to receive immediate LA CAB+RPV or to continue standard oral therapy until Week 24 (delayed switch group). The primary endpoint was the proportion of participants with an HIV-1 RNA level of less than 200 copies per milliliter at Week 24. RESULTS: Of 61 randomized participants, 45 met eligibility criteria and were included in the analysis; 91% were male, and the median baseline HIV-1 RNA was 35,000 copies/mL. At Week 24, viral suppression was achieved in 88.0% (22/25) in the immediate LA group versus 55.0% (11/20) in the delayed switch group (relative risk for failure to achieve viral suppression, 0.27; 95% CI, 0.08-0.86; p = 0.026). The effect of LA CAB+RPV was sustained through Week 52. CONCLUSIONS: Among people with HIV and viremia associated with adherence challenges, immediate initiation of LA CAB+RPV resulted in higher rates of viral suppression than continued oral ART, supporting its use beyond populations with stable suppression.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen NY, Chen CP, Lin YC, et al. Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial. Clin Infect Dis. 2026. PMID: 42678348. doi:10.1093/cid/ciag504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。